Table 1.
Basic characteristics of resected pancreatic cancer patients who were eligible to be included in the analysis
| Belgium
|
The Netherlands
|
Slovenia
|
||||
|---|---|---|---|---|---|---|
| ACT
|
ACT
|
ACT
|
||||
| Yes | No | Yes | No | Yes | No | |
| Available years of diagnosis | 2004–2013 | 2003–2014 | 2003–2013 | |||
| Follow-up until | July 1, 2015 | February 1, 2015 | May 25, 2016 | |||
| N (%) | 1,394 (56.9%) | 1,055 (43.1%) | 909 (35.5%) | 1,654 (64.5%) | 174 (26.5%) | 482 (73.5%) |
| Median time of ACT (IQR) | 9 (7–12) weeks | NA | 8 (6–11) weeks | NA | 9 (7–12) weeks | NA |
| Mean time of ACT (SD) | 10.2 (4.8) weeks | NA | 9.2 (4.6) weeks | NA | 10.6 (6.2) weeks | NA |
| Age (median [IQR]) | 64 (57–71) | 71 (63–76) | 64 (57–69) | 69 (61–74) | 62 (54–68) | 67 (58–74) |
| Age groups (%) | ||||||
| <60 | 462 (33.1) | 176 (16.7) | 291 (32.0) | 347 (21.0) | 72 (41.4) | 138 (28.6) |
| 60–69 | 510 (36.6) | 291 (27.6) | 398 (43.8) | 549 (33.2) | 69 (39.7) | 143 (29.7) |
| 70–79 | 393 (28.2) | 455 (43.1) | 215 (23.7) | 652 (39.4) | 33 (19.0) | 171 (35.5) |
| ≥80 | 29 (2.1) | 133 (12.6) | 5 (0.6) | 106 (6.4) | 0 (0.0) | 30 (6.2) |
| Sex (%) | ||||||
| Male | 736 (52.8) | 567 (53.7) | 454 (49.9) | 887 (53.6) | 97 (55.7) | 242 (50.2) |
| Female | 658 (47.2) | 488 (46.3) | 455 (50.1) | 767 (46.4) | 77 (44.3) | 240 (49.8) |
| Tumor location (%) | ||||||
| Head of pancreas | 785 (56.3) | 547 (51.8) | 746 (82.1) | 1,321 (79.9) | 126 (72.4) | 325 (67.4) |
| Body of pancreas | 69 (4.9) | 50 (4.7) | 28 (3.1) | 63 (3.8) | 13 (7.5) | 33 (6.8) |
| Tail of pancreas | 129 (9.3) | 76 (7.2) | 72 (7.9) | 132 (8.0) | 11 (6.3) | 33 (6.8) |
| Other/unspecified | 411 (29.5) | 382 (36.2) | 63 (6.9) | 138 (8.3) | 24 (13.8) | 91 (18.9) |
| Histology (%) | ||||||
| Acinar | 13 (0.9) | 14 (1.3) | 2 (0.2) | 13 (0.8) | 0 (0.0) | 3 (0.6) |
| Adenocarcinoma, NOS | 661 (47.4) | 494 (46.8) | 501 (55.1) | 991 (59.9) | 35 (20.1) | 104 (21.6) |
| Ductal | 647 (46.4) | 453 (42.9) | 358 (39.4) | 487 (29.4) | 125 (71.8) | 258 (53.5) |
| Intraductal | 23 (1.6) | 28 (2.7) | 10 (1.1) | 34 (2.1) | 0 (0.0) | 1 (0.2) |
| Mucinous | 5 (0.4) | 11 (1.0) | 6 (0.7) | 15 (0.9) | 1 (0.6) | 4 (0.8) |
| Other | 45 (3.2) | 55 (5.2) | 32 (3.5) | 114 (6.9) | 13 (7.5) | 112 (23.2) |
| Grade (%) | ||||||
| Well | 189 (13.6) | 154 (14.6) | 91 (10.0) | 153 (9.3) | 15 (8.6) | 61 (12.7) |
| Intermediate | 613 (44.0) | 401 (38.0) | 370 (40.7) | 718 (43.4) | 57 (32.8) | 131 (27.2) |
| Poor | 388 (27.8) | 271 (25.7) | 293 (32.2) | 467 (28.2) | 78 (44.8) | 174 (36.1) |
| Undifferentiated | 18 (1.3) | 19 (1.8) | 2 (0.2) | 4 (0.2) | 3 (1.7) | 8 (1.7) |
| Unknown | 186 (13.3) | 210 (19.9) | 153 (16.8) | 312 (18.9) | 21 (12.1) | 108 (22.4) |
| Spread (%) | ||||||
| Regional | 1,186 (85.1) | 760 (72.0) | 816 (89.8) | 1,284 (77.6) | 140 (80.5) | 351 (72.8) |
| Localized | 94 (6.7) | 230 (21.8) | 83 (9.1) | 309 (18.7) | 2 (1.1) | 60 (12.4) |
| Distant | 114 (8.2) | 65 (6.2) | 10 (1.1) | 61 (3.7) | 32 (18.4) | 71 (14.7) |
| Radiotherapy (%) | 185 (13.3) | 40 (3.8) | 5 (0.6) | 7 (0.4) | 14 (8.0) | 0 (0.0) |
| Previous other tumors (%) | 183 (13.1) | 159 (15.1) | 106 (11.7) | 253 (15.3) | NA | NA |
Abbreviations: ACT, adjuvant chemotherapy; IQR, interquartile range; NOS, not otherwise specified; SD, standard deviation; NA, not available.